文献速递复苏、休克与脓毒症呼吸衰竭与机械通气重症综合管理与镇静镇痛

新型冠状病毒肺炎患者中超说明书用药的使用差异:重症医学会发现病毒感染与呼吸系统疾病通用研究注册协作组报告

Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group.
PubMed 文献 · Crit Care Explor · 2021-11-02
一句话结论新冠疫情早期,76家医院对新冠住院患者超说明书用药差异极大(医院因素贡献30%-52%),随随机临床试验出现而趋同,用药高低与风险校正死亡率无差异。

该观察性队列研究纳入2020年2月15日至2021年4月12日期间美国及国际76家医院收治的7069例新冠住院成人,描述抗病毒药、糖皮质激素、羟氯喹、免疫调节剂和治疗剂量抗凝药的使用差异与演变。结果显示,医院因素对风险校正使用差异的贡献为:抗病毒药46%、糖皮质激素30%、羟氯喹48%、免疫调节剂46%、治疗剂量抗凝药52%。与疫情早期相比,疫情后期抗病毒药(OR 3.14;95%CI 2.40-4.10)和糖皮质激素(OR 5.43;95%CI 4.23-6.97)使用增加,羟氯喹(OR 0.02;95%CI 0.01-0.04)和免疫调节剂(OR 0.49;95%CI 0.34-0.70)使用减少,治疗剂量抗凝药无临床显著变化(OR 1.01;95%CI 1.01-1.02)。高用药率医院与低用药率医院的风险校正死亡率无差异。作者认为,需在下次大流行前建立快速启动和入组超说明书用药临床试验的平台,以加快循证实践。

要点

  • 7069例新冠住院成人中,抗病毒药使用1979例(28%)、糖皮质激素2876例(41%)、羟氯喹1779例(25%)、免疫调节剂620例(9%)、治疗剂量抗凝药2154例(31%)。
  • 医院因素对风险校正使用差异的贡献:抗病毒药46%、糖皮质激素30%、羟氯喹48%、免疫调节剂46%、治疗剂量抗凝药52%。
  • 疫情后期较早期:抗病毒药使用增加(OR 3.14;95%CI 2.40-4.10),糖皮质激素增加(OR 5.43;95%CI 4.23-6.97)。
  • 疫情后期较早期:羟氯喹使用减少(OR 0.02;95%CI 0.01-0.04),免疫调节剂减少(OR 0.49;95%CI 0.34-0.70)。
  • 高用药率医院与低用药率医院的风险校正死亡率无差异;治疗剂量抗凝药使用无临床显著变化(OR 1.01;95%CI 1.01-1.02)。

适用人群与场景

  • 2020年2月15日至2021年4月12日期间,美国及国际76家医院收治的新冠住院成人(7069例)。

研究设计与关键结果

  • 研究设计:观察性队列研究,纳入美国及国际76家医院7069例新冠住院成人。
  • 超说明书用药使用率:抗病毒药1979/7069(28%)、糖皮质激素2876/7069(41%)、羟氯喹1779/7069(25%)、免疫调节剂620/7069(9%)、治疗剂量抗凝药2154/7069(31%)。
  • 医院因素对风险校正使用差异的贡献:抗病毒药46%、糖皮质激素30%、羟氯喹48%、免疫调节剂46%、治疗剂量抗凝药52%。
  • 疫情后期较早期:抗病毒药使用增加(OR 3.14;95%CI 2.40-4.10),糖皮质激素增加(OR 5.43;95%CI 4.23-6.97)。
  • 疫情后期较早期:羟氯喹使用减少(OR 0.02;95%CI 0.01-0.04),免疫调节剂减少(OR 0.49;95%CI 0.34-0.70)。
  • 治疗剂量抗凝药使用无临床显著变化(OR 1.01;95%CI 1.01-1.02)。
  • 高用药率医院与低用药率医院的风险校正死亡率无差异。

证据类型、等级与局限

  • 证据类型:观察性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,需在下次大流行前建立快速启动和入组超说明书用药临床试验的平台,以加快有效、循证实践。

指南或共识出处

  • 重症医学会发现病毒感染与呼吸系统疾病通用研究(Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study)新冠病毒病2019注册协作组。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: At the start of the coronavirus disease 2019 pandemic, medications repurposed for management of coronavirus disease 2019 were used in the absence of clinical trial evidence.

OBJECTIVES: To describe the variation and evolution in use of repurposed medications for coronavirus disease 2019.

DESIGN SETTING AND PARTICIPANTS: Observational cohort study of adults hospitalized with coronavirus disease 2019 between February 15, 2020, and April 12, 2021, across 76 United States and international hospitals within the Society of Critical Care Medicine's Discovery Viral Infection and Respiratory Illness Universal Study coronavirus disease 2019 registry.

MAIN OUTCOMES AND MEASURES: Hospital variation was quantified using multivariable adjusted random effects logistic regression models and unsupervised clustering. Repurposed medications included antivirals, corticosteroids, hydroxychloroquine, immunomodulators, and therapeutic dose anticoagulants.

RESULTS: Among 7,069 adults hospitalized with coronavirus disease 2019, 1,979 (28%) received antivirals, 2,876 (41%) received corticosteroids, 1,779 (25%) received hydroxychloroquine, 620 (9%) received immunomodulators, and 2,154 (31%) received therapeutic dose anticoagulants. Contribution of hospital site to risk-adjusted variation was 46% for antivirals, 30% for corticosteroids, 48% for hydroxychloroquine, 46% for immunomodulators, and 52% for therapeutic dose anticoagulants. Compared with the early pandemic, the later pandemic practice phenotypes converged with increased use of antivirals (odds ratio, 3.14; 95% CI, 2.40-4.10) and corticosteroids (odds ratio, 5.43; 95% CI, 4.23-6.97), with decreased use of hydroxychloroquine (odds ratio, 0.02; 95% CI, 0.01-0.04) and immunomodulators (odds ratio, 0.49; 95% CI, 0.34-0.70). There was no clinically significant change in the use of therapeutic dose anticoagulants (odds ratio, 1.01; 95% CI, 1.01-1.02). There were no differences in risk-adjusted mortality between hospitals with high rates of repurposed medication use compared with hospitals with low rates of use.

CONCLUSIONS AND RELEVANCE: Hospital variation in the use of repurposed medications varied widely across hospitals early in the pandemic and later converged with the emergence of randomized clinical trials. Platforms developed for rapid activation and enrollment in clinical trials of repurposed medications are needed prior to the next pandemic to expedite effective, evidence-based practice.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Garcia MA, Johnson SW, Bosch NA, et al. Variation in Use of Repurposed Medications Among Patients With Coronavirus Disease 2019. From The Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study: Coronavirus Disease 2019 Registry Investigator Group. Crit Care Explor. 2021. PMID: 34746796. doi:10.1097/CCE.0000000000000566

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。